Verbindungen von Insulinpumpentherapie und kontinuierlichem Glukosemonitoring zur SuP – Der erste Schritt im Closed-Loop-System

Ein Closed-Loop-System ist die technische Lösung einer künstlichen Bauchspeicheldrüse, die sich Patienten mit Typ-1-Diabetes schon lange wünschen. Seitens der Hardware besteht dieses System aus einem Glukosesensor, der Insulinpumpe und einem Minicomputer, welcher die Insulinmenge errechnet und damit die Insulinabgabe steuert. Die Verbindung der Insulinpumpe mit dem kontinuierlichen Glukosemonitoring ist für die Patienten bereits verfügbar. Bei dem System MiniMed^®VEO greift der Glukosesensor sogar in die Steuerung der Insulinabgabe ein. Im Falle einer Hypoglykämie wird die Insulinabgabe automatisch unterbrochen und nach 2 Stunden wieder zugeschaltet, falls der Patient auf dabei auftretende Alarme nicht reagiert. Klinische Studien zeigen, dass damit schwere Hypoglykämien verhindert werden können. Das System kann als erste Stufe eines Closed-Loop-Systems verstanden werden.

A closed-loop system is the technical solution for an artificial pancreas. Patients with type 1 diabetes have long been looking for this. The Closed-Loop consists of a glucose sensor, the insulin pump and a mini computer, which calculates the amount of insulin and thereby controls the insulin delivery. The insulin pump MiniMed^®Veo is compatible with the continuous glucose monitoring and already available for patients. In this system the glucose sensor intervenes in controlling the insulin delivery. In case of hypoglycemia the insulin delivery is suspended automatically and again resumed after two hours, if the patient does not respond to the alarms that occurred. Clinical studies show that severe hypoglycemia can therefore be prevented. The system can be seen as the first step of a closed-loop system.

Key words

Artificial pancreas - closed-loop system - continuous glucose monitoring - sensor-augmented pump therapy - hypoglycemia shutdown (low glucose suspend)

• Literatur

• 1 Kadish AH. Automation control of blood sugar a servomechanism for glucose monitoring and control. Trans Am Soc Artif Intern Organs 1963; 9: 363-367
• 2 Albisser AM, Leibel BS, Ewart TG et al. An artifical endocrine pancreas. Diabetes 1974; 25: 389-396
• 3 Albisser AM, Leibel BS, Zinman B et al. Studies with an artifical endocrine pancreas. Arch Intern Med 1977; 137: 639-649
• 4 Feedback-Controlled and Preprogrammed Insulin Infusion in Diabetes Mellitus. Stuttgart, New York: Georg Thieme Verlag; 1978
• 5 Renard E, Panteleon AE, Leong P et al. Efficacy of Closed Loop Control of Blood Glucose Based on an Implantable IV Sensor and Intraperitoneal Insulin Pump. Diabetes 2004; 53 (Suppl. 02)
• 6 Kulcu E, Tamada JA, Reach G, Potts RO, Lesho MJ. Physiological Differences between Interstitial Glucose and Blood Glucose Measured in Human Subjects. Diabetes Care 2003; 26: 2405-2409
• 7 Liebl A, Henrichs HR, Heinemann L, Freckmann G, Biermann E, Thomas A. Arbeitsgruppe CGM der Arbeitsgemeinschaft Diabetologische Technologie der DDG (AGDT). Kontinuierliches Glukosemonitoring (CGM): Evidenz und Konsens für den klinischen Einsatz von CGM. Diabetes, Stoffwechsel und Herz 2012; 21: 32-47
• 8 Battelino T, Conget I, Olsen B et al. SWITCH Study Group. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012; 55: 3155-3162
• 9 Pickup JC, Freeman SC, Sutton AJ. The evidence base for CGM making sense of glucose sensors. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self-monitoring of blood glucose: Meta-analysis of randomised controlled trials using individual patient data. BMJ 2011; 343
• 10 Chase HP, Saib SZ, MacKenzie T, Hansen MM, Garg SK. Post-prandial glucose excursions following four methods of bolus insulin administration in subjects with Type 1 diabetes. Diabetic Medicine 2002; 19: 317-321
• 11 Ludwig-Seibold CU, Holder M, Rami B et al. DPV Science Initiative. Continuous glucose monitoring in children, adolescents, and adults with type 1 diabetes mellitus: analysis from the prospective DPV diabetes documentation and quality management system from Germany and Austria. Pediatric Diabetes 2012; 13: 12-14
• 12 Danne T, Kordonouri O, Holder M et al. Prevention of Hypoglycemia by Using Low Glucose Suspend Function in Sensor-Augmented Pump Therapy. Diabetes Technol Ther 2011; 13: 1129-1134
• 13 Choudhary P, Shin J, Wang Y et al. Insulin Pump TherapyWith Automated Insulin Suspension in Response to Hypoglycemia. Diabetes Care 2011; 34: 2023-2025
• 14 Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of Hypoglycemia and Cardiac Ischemia: A Study Based on Continuous Monitoring. Diabetes Care 2003; 26: 1485-1489
• 15 Gill GV, Woodward A, Casson IF, Weston PJ. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes - the 'dead in bed' syndrome revisited. Diabetologia 2009; 52: 42-45
• 16 Veglio M, Sivieri R, Chinaglia A, Scaglione L, Perin PC. QT Interval Prolongation and Mortality in Type 1 Diabetic Patients. A 5-year cohort prospective study. Diabetes Care 2000; 23: 1381-1383
• 17 Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest 1987; 79: 777-781
• 18 Fanelli C, Pampanelli S, Epifano L et al. Relative roles of insulin and hypoglycemia on induction of neuroendocrine responses to, symptoms of, and deterioration of cognitive function in hypoglycemia in male and female humans. Diabetologia 1994; 37: 797-807
• 19 Cryer PE. Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II Diabetes. Diabetologia 2002; 45: 937-948
• 20 Ly TT, Nicolas JA, Retterath A et al. Effect of Sensor-Augmented Insulin Pump Therapy and Automated Insulin Suspension vs Standard Insulin Pump Therapy in Patients with Type 1 Diabetes . A Randomized Clinical Trial. JAMA 2013; 310: 1240-1247